Lots more info (including state-specific relevant to your situation) at ccf.georgetown.edu and www.kff.org

3. That makes it one of our most important tools for ensuring equity (slide courtesy of Dr. Shah)

Bonus content: A fascinating interview about the paper with Drs. Philip Sunshine and William Northway
youtu.be/79prakcjBjc?...
6/6

Case reports and series may be prone to bias, but in the hands of committed scientists, observation is still the entry point to improved outcome.
5/6

…including progression of disease with path, clinical, radiological lenses; very early discussion of acquired pulmonary hypertension; role of oxygen; separation of two overlapping disease entities with eventual demonstration of distinct treatment modalities.
4/6

For your consideration:
Careful description, with no statistical comparisons, still brought a number of lasting truths to the table in this first comprehensive description of BPD…
3/6

From the article: “The two outstanding findings are the prolongation of the healing phase of [RDS} and the appearance of a new chronic pulmonary syndrome that is associated with intermittent positive pressure respirators and High Oxygen for longer than one hundred and fifty hours (six days).”
2/6...

ROBINS-I v2: www.riskofbias.info/welcome/robi...

GRADE obviously also supports this broadly within a given review at the body-of-literature level.

I am not sure that we have Cochrane NRSI SRMA examples in neonatology yet. Might be worth taking one on in the above area as a pilot?

But there has always been rx evidence beyond RCTs (just think what we got from the Framingham study). Cochrane has expanded its charter to non-randomised studies of the effects of interventions (NRSIs) and is developing tools to support that endeavor (eg see the observational RoB tool ROBINS-I v2)

It's such an important point @briankingneo.bsky.social . SRMAs with few or no RCTs are of course an essential part of the evidence synthesis process - I suspect that @souvikneo.bsky.social's review might find itself into the rationale for a new CIHR trial application or two :)

Great! Dr. Saigal is always happy to hear from people if you have questions or comments.

(The #52MoreChallenge is a follow-up of the #52in52RCTChallenge. We're currently replaying the first month from Twitter and will start new articles in week 5. If you have candidates for the 52 most important non-RCT articles in the #NeoSky literature, please let me know)

Follow-up bonus about follow-up: Dr. Saigal interviewed the now-adult members of the same cohort decades later for a less prosaic, and quite moving, book and accompanying videos. See a.co/d/411zd3u and www.youtube.com/@PreemieVoices (the latter with both 2014 and 2024 interviews)
🧵fin

From the paper: “Nevertheless, the vast majority of ELBW respondents view their health-related quality of life as quite satisfactory and are difficult to distinguish from controls."
🧵4/5

The participants in this work were part of a long-term, geographically-defined (and therefore low-selection-bias) cohort, also a significant contribution to a literature that had been (and remains) plagued by single-center, short-term studies.
🧵3/5

Dr. Saroj Saigal took to heart the insight that EBM includes not only critical appraisal but also patient values & preferences. Her research used tools f/ economics & psychology to demonstrate that patients & families may have different impressions of their own 'medical sequelae' than expected.
🧵2/5